ClinicalTrials.gg
CompletedNCT01708174Updated Aug 11, 2017Results posted

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

A Phase 2 interventional study of LDE225 and TMZ in Medulloblastoma, sponsored by Novartis Pharmaceuticals. Completed at 41 sites in 13 countries. Open to participants aged 4 Months and older. Per ClinicalTrials.gov, last updated 2017-08-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
4 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Enrollment
136th of 215
22 · median 30
Started
2013
with 10 others
Phase 2
65 of 245
5 open now
Registered
135th of 245
by date
Lead sponsor
6 of 245
Novartis Pharmaceuticals

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 136th largest by enrollment of the 215 interventional ones that give a count, is one of 11 that started in 2013, is one of 65 in phase 2, and was the 135th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 51 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 31 (84%) stop at 75 or younger; 34 take children under 18; 1 takes healthy volunteers.

This study: 4 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.

Read the detailed description

This study was a single-arm study of the efficacy and safety of oral sonidegib in patients with Hh-pathway activated relapsed medulloblastoma. It was initially designed as a randomized, controlled, open-label phase III study of adults and children with Hh-pathway activated MB whose disease had failed standard of care therapy, including radiation therapy (RT). The original study consisted of a randomized controlled part and a non-randomized uncontrolled part. Approximately 69 patients were to be randomized in a 2:1 ratio to receive sonidegib oral suspension or the active control, temozolomide (TMZ) capsules. Randomization was to be stratified according to age, \<18 years versus ≥ 18 years. Approximately 40 patients were to receive sonidegib in the non-randomized uncontrolled part of the study. Following the enrollment of 11 patients, the study was amended to become a phase II single-arm study with only sonidegib, and the target enrollment was changed to 20 patients. Prior to the study amendment, TMZ participants whose disease progressed while on TMZ were permitted to crossover to sonidegib. After the amendment, participants receiving TMZ were crossed over to sonidegib.

03

Conditions studied

  • Medulloblastoma

Keywords

  • medulloblastoma,
  • relapsed,
  • pediatric,
  • children,
  • adults,
  • Hh pathway inhibitor,
  • LDE225
04

Who can participate

Ages eligible
4 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed diagnosis of MB, who have experienced relapse or progression after standard-of-care therapy including radiotherapy. Patients currently receiving must have been on a stable (or decreasing) dose for at least 5 days before initiating study therapy.
  • Only patients with a test result, using the 5-gene Hh signature assay, indicating Hhpathway activated MB are eligible for this study. All available tumor material obtained at any time during the course of the patient's disease should be submitted for these analyses
  • At least one defined as lesion(s) that can be accurately measured in at least two dimensions and is ≥ 10 mm in each dimension by Gadolinium (Gd)-MRI, irrespective of slice thickness/reconstruction interval, for CNS lesions and CT or MRI (with or without contrast) for non-CNS lesions. All patients with CNS lesions must have a brain MRI with and without gadolinium and a spine MRI with gadolinium within 2 weeks prior to first dose of study treatment.
  • Performance Status corresponding to score of 0, 1, or 2:

    1. performance status score ≥ 50 for patients >16 years of age
    2. Lansky performance status score ≥ 50 for patients ≤ 16 years of age
  • Adequate bone marrow function as defined as:

    1. Peripheral (ANC) ≥ 1.5 x 109/L
    2. count ≥ 80 x 109/L
    3. (Hgb) ≥ 9 g/dL
  • Serum CK ≤1.5

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a Smoothened inhibitor Systemic anticancer treatment within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies).
  • Focal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months before first dose of study treatment.
  • Patients who have neuromuscular disorders that are associated with elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • Patients receiving treatment with medications that are known to be strong inhibitors or inducers of /5 or are metabolized by CYP2B6 and CYP2C9, that have narrow therapeutic indices that cannot be discontinued at least 2 weeks before first dose of study treatment and for the duration of the study
  • Patients receiving unstable or increasing doses of . If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Sonidegib (LDE225)

    600 mg orally for adults and 500 mg/m2 orally for children

    Drug: LDE225

  • Active comparator
    Temozolamide (TMZ)

    150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.

    Drug: TMZ

Interventions

  • DrugLDE225

    Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.

  • DrugTMZ

    Temozolomide capsules were obtained locally by the Investigator

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). Assessments after crossover were not included for TMZ participants.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

Secondary outcomes

  1. Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). TMZ participants without event prior to crossover were censored.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

  2. PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause. PFS was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

  3. Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). ORR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. Assessments after crossover were not included for TMZ patients.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

  4. Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    DoR was defined as the time from the first documented onset of confirmed PR or CR to the date of PD/relapse or death due to medulloblastoma. DoR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. TMZ participants without an event prior to crossover were censored.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

  5. Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

    OS was defined as the time from date of randomization to date of death due to any cause. All deaths are considered, including deaths occurred after crossover for TMZ participants.

    Time frame: from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016

  6. Pharmacokinetics (PK): Summary of Plasma Trough Concentrations for Sonidegib (LDE225)

    Blood samples were collected for assessment. The children's group was analyzed up until week 25 only.

    Time frame: Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and 53

07

Results

Posted Jun 14, 2017

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Started2164
Pharmacokinetic analysis set2130
Completed1143
Not completed121
Withdrew: Withdrawal by subject100
Withdrew: Progressive disease010
Withdrew: Death001
Withdrew: Adverse event010
Survival Follow-up
Participant flow — Survival Follow-up
MilestoneSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Started1100
Completed1100
Not completed000

Outcome measures

PrimaryPercentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). Assessments after crossover were not included for TMZ participants.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
Percentage of participantsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-20160.018.80.0
SecondaryProgression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause (as per tumor response guidelines and criteria for Medulloblastoma). The IRC evaluated all radiological images and applicable clinical data (i.e., neurological examination, steroid use and cerebrospinal fluid (CSF) results as applicable). TMZ participants without event prior to crossover were censored.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Median · months
Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
monthsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Progression Free Survival (PFS) According to IRC From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-20161.6 (NA to NA)3.3 (1.7 to 17.1)2.9 (0.9 to 4.0)
SecondaryPFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

PFS was defined as the time from date of randomization to the date of event defined as the first documented progression or death due to any cause. PFS was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Median · months
PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
monthsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
PFS According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016NA (1.6 to NA)3.3 (1.6 to 13.0)2.9 (0.9 to 4.0)
SecondaryPercentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR). ORR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. Assessments after crossover were not included for TMZ patients.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Number · Percentage of participants
Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
Percentage of participantsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Percentage of Participants With ORR According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-20160.025.00.0
SecondaryDuration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

DoR was defined as the time from the first documented onset of confirmed PR or CR to the date of PD/relapse or death due to medulloblastoma. DoR was evaluated by local Investigator assessment per tumor response guidelines and criteria for Medulloblastoma. TMZ participants without an event prior to crossover were censored.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Median · months
Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
monthsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Duration of Response (DoR) According to Local Investigator Assessment From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016NA (NA to NA)8.5 (4.1 to 16.6)NA (NA to NA)
SecondaryOverall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016

OS was defined as the time from date of randomization to date of death due to any cause. All deaths are considered, including deaths occurred after crossover for TMZ participants.

Time frame:
from date first participant randomized, 13-Sep-2013 to date of data cut-off, 15-Nov-2016
Reported as:
Median · months
Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016
monthsSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)
Overall Survival (OS) From Date First Participant Randomized, 13-Sep-2013 to Date of Data Cut-off, 15-Nov-2016NA (4.5 to NA)9.5 (4.9 to 15.6)NA (1.2 to NA)
SecondaryPharmacokinetics (PK): Summary of Plasma Trough Concentrations for Sonidegib (LDE225)

Blood samples were collected for assessment. The children's group was analyzed up until week 25 only.

Time frame:
Weeks 1, 3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49 and 53
Reported as:
Mean · ng/mL
Pharmacokinetics (PK): Summary of Plasma Trough Concentrations for Sonidegib (LDE225)
ng/mLSonidegib (LDE225) ChildrenSonidegib (LDE225) Adults
Week 1 (n=2,11)0.00 ± 0.000.00 ± 0.00
Week 3 (n=2,10)2890 ± 1240761 ± 519
Week 5 (n=2,8)4930 ± 13801090 ± 700
Week 7 (n=1,8)2810 ± NA1450 ± 842
Week 9 (n=1,8)4670 ± NA1530 ± 682
Week 13 (n=1,4)3680 ± NA2330 ± 1100
Week 17 (n=1,6)3060 ± NA1880 ± 730
Week 21 (n=1,5)3770 ± NA2270 ± 915
Week 25 (n=1,4)1890 ± NA2050 ± 625
Week 29 (n=NA,4)NA ± NA2050 ± 906
Week 33 (n=NA,4)NA ± NA2180 ± 512
Week 37 (n=NA,3)NA ± NA2850 ± 306
Week 41 (n=NA,4)NA ± NA2370 ± 916
Week 45 (n=NA,2)NA ± NA2890 ± 290
Week 49 (n=NA,2)NA ± NA2330 ± 990
Week 53 (n=NA,2)NA ± NA2080 ± 764

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sonidegib (LDE225) Children—2/2 (100%)2/2 (100%)
Sonidegib (LDE225) Adults—9/16 (56.3%)16/16 (100%)
Sonidegib (Total)—11/18 (61.1%)18/18 (100%)
Temozolomide (TMZ)—1/4 (25%)4/4 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsSonidegib (Total)Temozolomide (TMZ)
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders1/20/161/180/4
THROMBOSIS IN DEVICEProduct Issues1/20/161/180/4
NECK PAINMusculoskeletal and connective tissue disorders0/20/160/181/4
VOMITINGGastrointestinal disorders0/22/162/180/4
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/22/162/180/4
NAUSEAGastrointestinal disorders0/21/161/180/4
PAINGeneral disorders0/21/161/180/4
BACTERIAL SEPSISInfections and infestations0/21/161/180/4
CLOSTRIDIAL INFECTIONInfections and infestations0/21/161/180/4
LUNG INFECTIONInfections and infestations0/21/161/180/4
Most frequent other events
Showing 10 of 127
Most frequent other events
EventSonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsSonidegib (Total)Temozolomide (TMZ)
VOMITINGGastrointestinal disorders2/27/169/181/4
HEADACHENervous system disorders2/23/165/181/4
ALOPECIASkin and subcutaneous tissue disorders2/26/168/180/4
NAUSEAGastrointestinal disorders0/25/165/183/4
DIARRHOEAGastrointestinal disorders1/23/164/180/4
FATIGUEGeneral disorders0/27/167/182/4
ORAL HERPESInfections and infestations1/20/161/180/4
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations1/27/168/181/4
BLOOD CREATINE PHOSPHOKINASE MB INCREASEDInvestigations1/21/162/181/4
MYALGIAMusculoskeletal and connective tissue disorders1/25/166/180/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)Total
Median8.5 ± 6.3637.0 ± 8.1735.5 ± 3.1635.0 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)Sonidegib (LDE225) ChildrenSonidegib (LDE225) AdultsTemozolomide (TMZ)Total
Female2529
Male011213
08

Study locations

41 sites
  • Ann & Robert H. Lurie Children Dept of Oncology
    Chicago, Illinois 60611, United States
  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Dept Onc
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute SC-7
    Boston, Massachusetts 02215, United States
  • Columbia University Medical Center- New York Presbyterian Dept of Oncology
    New York, New York 10032, United States
  • Cincinnati Children's Hospital Medical Center Division of Hema/Onco.
    Cincinnati, Ohio 45229-3039, United States
  • Children's Hospital of Pittsburgh Dept of Oncology
    Pittsburgh, Pennsylvania 15213-2583, United States
  • University of Texas/MD Anderson Cancer Center SC-3
    Houston, Texas 77030-4009, United States
  • Seattle Cancer Care Alliance Dept Oncology
    Seattle, Washington 98105, United States
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6840, Australia
  • Novartis Investigative Site
    Sao Paulo, SP, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 1Z6, Canada
  • Novartis Investigative Site
    Bordeaux, Aquitaine 33076, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Lille Cedex, 59020, France
  • Novartis Investigative Site
    Paris, 75231, France
  • Novartis Investigative Site
    Toulouse Cedex 9, 31059, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy, 54511, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Augsburg, 86156, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Bologna, BO 40139, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Torino, TO 101126, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Rotterdam, 3015 CN, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3075 EA, Netherlands
  • Novartis Investigative Site
    Moskow, Russia 117198, Russian Federation
  • Novartis Investigative Site
    Sevilla, Andalucia 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Esplugues de Llobregat, Catalunya 08950, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Goteborg, 413 45, Sweden
  • Novartis Investigative Site
    Zürich, 8032, Switzerland
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Oct 2016, 40 months.

Results were first posted in Jun 2017, 8 months after primary completion.

Of 42 phase 2 interventional studies under Medulloblastoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 92. This study's 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2012
First posted
Oct 16, 2012
StartActual
May 6, 2013
Primary completionActual
Oct 5, 2016
CompletionActual
Oct 5, 2016
Results first posted
Jun 14, 2017
Last update
Aug 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01708174
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
May 6, 2013
Primary completion
Oct 5, 2016
Completion
Oct 5, 2016
Results posted
Jun 14, 2017
Last update
Aug 11, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion